Lonza Group AG Lonza Group AG

Lonza Group AG

LONN

Rangering i aksjer #446
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aksjekurs
$763.79
Markedsverdi
$53.35B
Endring (1 dag)
0.93%
Endring (1 år)
8.56%
Land
CH
Handel Lonza Group AG (LONN)

Kategori

Healthcare
Aksjeprishistorikk for Lonza Group AG (LONN)
Høyeste sluttskurs: $758.47 den 2026-10-01

Laveste sluttskurs: $55.45 den 1999-11-01
Aksjeprishistorikk for Lonza Group AG fra 1999 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) 2.71%
2025 12.69%
2024 52.26%
2023 -21.39%
2022 -38.27%
2021 29.85%
2020 78.48%
2019 17.36%
2018 12.75%
2017 66.47%
2016 7.54%
2015 39.65%
2014 24.10%
2013 74.91%
2012 -11.33%
2011 -26.82%
2010 12.01%
2009 -13.00%
2008 -29.50%
2007 34.20%
2006 46.37%
2005 8.46%
2004 5.02%
2003 -11.00%
2002 -13.66%
2001 22.46%
2000 -6.51%
1999 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$536.13 25.72%
US
$200.12 645.31%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$880.01 8.09%
NL